US02155H2004 - Common Stock
ALTIMMUNE INC
NASDAQ:ALT (4/18/2024, 12:52:01 PM)
7.14
+0.1 (+1.42%)
Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company is headquartered in Gaithersburg, Maryland and currently employs 52 full-time employees. The company went IPO on 2005-10-06. The Company’s lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis (NASH). The company is also developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B. The firm has initiated a Phase II clinical trial of HepTcell and is in Phase II and Phase I clinical development with pemvidutide for multiple indications. The company is conducting its Phase II clinical trial of HepTcell in the United States, United Kingdom, Canada, Germany Spain and Thailand. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.
ALTIMMUNE INC
910 Clopper Rd Ste 201S
Gaithersburg MARYLAND 20878
P: 12406541450
CEO: Vipin K. Garg
Employees: 52
Website: https://altimmune.com/
Biotech stocks can offer some of the most explosive, exciting opportunities on the market.That is, if you find the right one.
Viking Therapeutics has garnered a lot of attention following a successful clinical trial for its obesity care drug. But another development-stage biotech may have a superior candidate.
The stock market rally showed breadth, with small caps leading the way to a 24-month high. Growth leaders like Nvidia took a break.
ALT stock results show that Altimmune beat analyst estimates for earnings per share the fourth quarter of 2023.
Here you can normally see the latest stock twits on ALT, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: